

Redemplo (plozasiran) Utilization Management Criteria

Non-Preferred Agents:	Redemplo (plozasiran)
Implementation Date:	10/1/2026
Prepared For:	CT
PDL Status:	Non-preferred
Purpose:	Familial chylomicronemia syndrome (FCS) is a rare genetic condition characterized by severely elevated triglyceride levels. Patients with FCS are at risk for recurrent and potentially life-threatening, acute pancreatitis. Traditional triglyceride lowering medications are generally not effective in FCS. Redemplo is one of two FDA approved products to treat FCS and should be used alongside a low fat diet to reduce triglycerides. The most common adverse reactions were hyperglycemia, headache, nausea, and injection site reactions.

Table 1. Redemplo

Generic Name	Brand Name	Approved Indications	Route of Administration	Generic Availability
Plozasiran	Redemplo®	Familial chylomicronemia syndrome (FCS)	Subcutaneous	N/A

All authorizations must be prescribed in accordance with FDA approved labeling. Use of samples to initiate therapy does not meet continuation of therapy prior authorization requirements. Prior therapies will be verified through pharmacy claims and/or submitted chart notes.

Initial Therapy – All the following must be met:

- Patient aged 18 years old and older
- Prescribed by or in consultation with a specialist familiar with managing FCS (e.g. lipidologist, cardiologist, gastroenterologist, endocrinologist, pancreatologist)
- Confirmation of FCS diagnosis by **ONE** of the following:
 - Confirmation of FCS via genetic testing
 - History of fasting triglyceride level of more than 1,000 mg/dL on at least 3 occasions and at least one of the following:
 - Absent or low postheparin lipoprotein lipase activity (<20% of normal)
 - History of acute pancreatitis not caused by alcohol or cholelithiasis
 - Recurrent hospitalization for severe abdominal pain without other identified cause
 - History of childhood pancreatitis
 - Family history of hypertriglyceridemia-induced pancreatitis
 - Patient has a Moulin score of ≥ 10
 - Patient has a NAFCS score ≥ 60
- Provider attests that Redemplo will be used in conjunction with lifestyle modifications, including a

low fat diet (< 20 g/day)

- Redemplo will not be used in combination with Tryngolza
- Maximum quantity: One (25 mg) syringe every 3 months

Initial PA length: 1 year

Exclusion Criteria: Approval criteria not met

Continuation Therapy: Documented compliance on current therapy regimen AND Provider attests to continued clinical benefit

Continuation Length: 1 year

References:

1. Drugs@FDA: FDA Approved Drug Products. Accessed January 2025. <https://www.accessdata.fda.gov/scripts/cder/daf/>
2. DailyMed: National Library of Medicine. Accessed July 2026. <https://dailymed.nlm.nih.gov/dailymed/index.cfm>
3. National Organization for Rare Disorders (2025). Familial Chylomicronemia Syndrome. Accessed February 9, 2026. <https://rarediseases.org/rare-diseases/familial-chylomicronemia-syndrome/>
4. Redemplo (plozasiran) [prescribing information]. Pasadena, Ca; Arrowhead Pharmaceuticals, Inc. 2025
5. Javed F, et al. Familial chylomicronemia syndrome: An expert clinical review from the National Lipid Association. *J Clin Lipidol.* 2025;19(3):382-403. doi:10.1016/j.jacl.2025.03.013
6. Watts GF, Rosenson RS, Hegele RA, et al. Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk. *N Engl J Med.* 2025;392(2):127-137. doi:10.1056/NEJMoa2409368
7. IPD Analytics. New Drug Review: Redemplo (plozasiran). December 2025. Accessed February 10, 2026. <https://ipdanalytics.com>.
8. Moulin P, Dufour R, Averna M, et al. Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an "FCS score". *Atherosclerosis.* 2018;275:265-272. doi:10.1016/j.atherosclerosis.2018.06.814
9. Hegele RA, Ahmad Z, Ashraf A, et al. Development and validation of clinical criteria to identify familial chylomicronemia syndrome (FCS) in North America. *J Clin Lipidol.* 2025;19(1):83-94. doi:10.1016/j.jacl.2024.09.008

Revision History

Date	Version	Revisions
7/31/2026	V1	Document approved by DSS